Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2021 Apr 09

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Medica 2021 Apr 09

DOI: 10.23736/S0026-4806.21.07537-6

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Adenosine and neurohumoral syncope

Jean-Claude DEHARO 1 , Michele BRIGNOLE 2, Régis GUIEU 3

1 Department of Cardiology, Hôpital La Timone Adultes, and C2VN INSERM, INRAE, Aix Marseille University, Marseille, France; 2 Department of Cardiovascular, Neural and Metabolic Sciences, Faint & Fall Programme, IRCCS Istituto Auxologico Italiano, Ospedale San Luca, Milan, Italy; 3 Laboratory of Biochemistry, Timone Hospital and C2VN INSERM, INRAE, Aix Marseille University, Marseille, France


PDF


Either central or peripheral baroreceptor reflex abnormalities and/or alterations in neurohumoral mechanisms play a pivotal role in the genesis of neurally mediated syncope. Thus, improving our knowledge of the biochemical mechanisms underlying specific forms of neurally mediated syncope (more properly termed ‘neurohumoral syncope’) might allow the development of new therapies that are effective in this specific subgroup. A low-adenosine phenotype of neurohumoral syncope has recently been identified. Patients who suffer syncope without prodromes and have a normal heart display a purinergic profile which is the opposite of that observed in vasovagal syncope patients and is characterized by very lowadenosine plasma level values, low expression of A2A receptors and the predominance of the TC variant in the single nucleotide c.1364 C>T polymorphism of the A2A receptor gene. The typical mechanism of syncope is an idiopathic paroxysmal atrioventricular block or sinus bradycardia, most often followed by sinus arrest. Since patients with low plasma adenosine levels are highly susceptible to endogenous adenosine, chronic treatment of these patients with theophylline, a non-selective adenosine receptor antagonist, is expected to prevent syncopal recurrences. This hypothesis is supported by results from series of cases and from two controlled studies.


KEY WORDS: Adenosine; Syncope; Neurally mediated syncope; Theophylline; Xanthine

inizio pagina